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Abstract
Background: Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors and commonly
play an important role in the regulation of lipid homeostasis. To identify human PPARs-responsive genes, we established
tetracycline-regulated human hepatoblastoma cell lines that can be induced to express each human PPAR and investigated the
gene expression profiles of these cells.
Results: The expression of each introduced PPAR gene was investigated using the various concentrations of doxycycline in the
culture media. We found that the expression of each PPAR subtype was tightly controlled by the concentration of doxycycline
in these established cell lines. DNA microarray analyses using these cell lines were performed with or without adding each
subtype ligand and provided much important information on the PPAR target genes involved in lipid metabolism, transport,
storage and other activities. Interestingly, it was noted that while ligand-activated PPARδ induced target gene expression,
unliganded PPARδ repressed these genes. The real-time RT-PCR was used to verify the altered expression of selected genes by
PPARs and we found that these genes were induced to express in the same pattern as detected in the microarray analyses.
Furthermore, we analysed the 5'-flanking region of the human adipose differentiation-related protein (adrp) gene that responded to
all subtypes of PPARs. From the detailed analyses by reporter assays, the EMSAs, and ChIP assays, we determined the functional
PPRE of the human adrp gene.
Conclusion: The results suggest that these cell lines are important tools used to identify the human PPARs-responsive genes.
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Background
The peroxisome proliferator-activated receptors (PPARs)
are ligand-activated transcription factors that belong to
the nuclear hormone receptor superfamily [1]. Three sub-
types, PPARα, PPARβ/δ and PPARγ, have been identified
and these subtypes with a high degree of sequence conser-
vation of each subtype across various species, have been
characterized. The DNA binding domains of the three
subtypes are 80% identical, while their ligand-binding
domains exhibit a lower degree (approx. 65%) of identity.
Consistent with this relatively high divergence among the
subtype-specific ligand binding domains, differential acti-
vation of PPARs by endogenous and exogenous com-
pounds may account for the specific biological activity of
the three PPAR subtypes [2,3].
PPARα is expressed in the liver, kidney, heart and muscle
where it regulates energy homeostasis. PPARα activates
fatty acid catabolism, stimulates gluconeogenesis and
ketone body synthesis and is involved in the control of
lipoprotein assembly [4]. Although PPARα is well charac-
terized, the functional differences of PPARα derived from
species are not clear. For example, sustained PPARα acti-
vation has carcinogenic consequences in the liver of
rodents, but long-term usage of PPARα activators in epi-
demiological data, has proven that similar effects are
unlikely to occur in humans [5,6]. PPARδ is expressed
ubiquitously, and is implicated in fatty acid oxidation, in
keratinocyte differentiation and wound healing, and in
mediating very low density lipoprotein signalling of the
macrophage [7-11]. However, the function of PPARδ is
less understood than PPARα and γ. There are two PPARγ
isoforms, PPARγ1 and γ2. PPARγ2, which is generated by
alternative splicing, contains an additional 28 amino
acids at the N-terminal end relative to PPARγ1. PPARγ3 is
a splicing variant of PPARγ1 and gives rise to the same
protein. PPARγ2 is expressed exclusively in adipose tissue
and has a pivotal role in adipocyte differentiation, lipid
storage in the white adipose tissue and energy dissipation
in the brown adipose tissue [12,13]. On the other hand,
PPARγ1 is expressed in the liver and other tissues, and the
expression of hepatic PPARγ is increased in some obese
and diabetic model mice [14-17]. PPARγ is involved in
glucose metabolism through the improvement of insulin
sensitivity; however, its function is not well defined.
All PPARs bind to a direct repeat of two hexanucleotides,
spaced by one or two nucleotides (the DR1 or DR2 motif)
as heterodimers with the retinoid X receptor (RXR), and
activate several target genes [18-20]. These peroxisome
proliferator responsive elements (PPREs) are found in var-
ious genes that are involved in lipid metabolism and
energy homeostasis, including lipid storage or catabolism,
and fatty acid transport, uptake and intracellular binding
[21].
One of the approaches for investigating target genes of
PPARs is to construct stable cell lines that can be induced
to express PPARs. The tet-off system is a well-established
system for inducible gene expression. In this system, tran-
scription is turned on or off in response to doxycycline
(Dox; a tetracycline derivative) in a strictly dose-depend-
ent manner. Therefore, background or leaky expression in
the absence of induction is extremely low. The tet-off sys-
tem enables us to compare the same cell line before and
after induction of the gene of interest. Previously, we
established the human hepatoblastoma cell lines (HepG2
cells) which were strictly induced to express the hepatitis
C non-structural proteins by removing Dox from the
media, and we characterized the changes in mRNA expres-
sion profile using DNA microarray analyses [22].
In the present study, to identify human PPARs-responsive
genes in the liver cell line, we established tightly tet-regu-
latable HepG2 cells which can be induced to express each
human PPAR. We demonstrated that human PPARs are
important regulators of lipid homeostasis in these cell
lines using DNA microarray and real-time RT-PCR tech-
nologies. Subsequent analyses revealed that all PPARs
induced human adipose differentiation-related protein (adrp)
gene expression through the same PPRE of the ADRP pro-
moter, while unliganded PPARδ repressed this gene. Our
results imply that these cell lines are important tools,
which can be used to identify the human PPARs-respon-
sive genes.
Results
Establishment of HepG2 cells that can be induced to 
express PPARs
To identify human PPARs-responsive genes, we estab-
lished each cell line that expresses any one of the PPAR
subtypes (α, β/δ, γ1 or γ2) using the tet-regulated system.
Previously, we established the tightly tet-regulatable
HepG2 cell clone (HY-Toff) which was transfected with
the pTet-off vector, and that this clone had a large induc-
tion/repression rate [22]. The tet-off regulatable HY-Toff
cells were transfected with the pBabepuro (for puromycin
resistance) and pBI-EGFP vector harbouring the cDNA for
human PPARα, PPARδ, PPARγ1 or PPARγ2. We picked out
puromycin-resistant clones. Among these clones, we
selected the strictly responsive cell lines (HepG2-tet-off-
hPPAR cells) to the concentration of Dox. These cell lines
were cultured in the presence of Dox at 0, 0.01, 0.1 or
1000 ng/ml for 5 days, and we found that PPARs expres-
sion in these cell lines was induced in a dose-dependent
manner (Figure 1A–D). We then examined the time
course experiment of each PPAR expression after the
removal of Dox. The results showed that both the mRNA
(Figure 2A–D) and protein (Figure 2E–H) levels of each
PPAR were increased after the removal of Dox from the
culture medium. Under these conditions, cellNuclear Receptor 2005, 3:3 http://www.nuclear-receptor.com/content/3/1/3
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Induction of the expression of PPAR by doxycycline in established cell lines Figure 1
Induction of the expression of PPAR by doxycycline in established cell lines. A, B, C and D, Nuclear extracts (50 µg 
protein/lane) from each cell line cultured in the presence of the indicated amounts of Dox for 5 days were subjected to SDS-
PAGE and immunoblots were performed with anti-PPARα (A), anti-PPARδ (B) or anti-PPARγ (C and D).Nuclear Receptor 2005, 3:3 http://www.nuclear-receptor.com/content/3/1/3
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Time course of PPAR expression in established cell lines Figure 2
Time course of PPAR expression in established cell lines. A, B, C and D, The cell lines for the expression of PPARα (A), 
PPARδ (B), PPARγ1 (C) or PPARγ2 (D) were cultured in the presence of Dox. At time point 0, Dox was removed from the 
medium. The total RNAs were extracted from the cells cultured for the indicated days after removal of Dox and the amount 
of mRNAs of PPARs were measured by real time RT-PCR. Values are expressed as the mean ± S.E.M. (n = 3), relative to the 
control (0 day) set as 1. E, F, G and H, Nuclear extracts (50 µg protein/lane) from the cell lines expressing PPARα (E), PPARδ 
(F), PPARγ1 (G) or PPARγ2 (H) cultured for the indicated days after removal of Dox were subjected to SDS-PAGE and immu-
noblots were performed with anti-PPARα (E), anti-PPARδ (F) or anti-PPARγ (G and H).N
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Table 1: Changes in mRNA expression levels of metabolism-related genes in HepG2-tet-off-hPPAR cells by ligands. Microarray analyses were performed on HepG2-tet-off-
hPPAR cells; the cells were cultured in the presence (Dox) or absence of Dox for 5 days. In the absence of Dox, the cells were treated with PPAR ligands (100 µM fenofibric acid 
for PPARα (Feno), 100 nM GW501516 for PPARδ (GW) or 10 µM ciglitizone for PPARγ (Cig)) or vehicle (DMSO) for 24 h. Gene expression profiles were compared between 
DMSO and Dox (DMSO versus Dox), ligands and Dox (Feno versus Dox, GW versus Dox, and Cig versus Dox were indicated in the case of PPARα, PPARδ and PPARγ, 
respectively) or ligands and DMSO (Feno versus DMSO, GW versus DMSO, and Cig versus DMSO were indicated in the case of PPARα, PPARδ and PPARγ, respectively). Samples 
were analysed using GeneChip® software Microarray Suite (MAS) Ver.5.0 (Affymetrix).
Gene Genbank 
accession No.
PPARα PPARδ PPARγ1 PPARγ2
Fold change Fold change Fold change Fold change
DMSO 
vs. Dox
Feno 
vs. Dox
Feno vs. 
DMSO
DMSO 
vs. Dox
GW vs. 
Dox
GW vs. 
DMSO
DMSO 
vs. Dox
Cig vs. 
Dox
Cig vs. 
DMSO
DMSO 
vs. Dox
Cig vs. 
Dox
Cig vs. 
DMSO
Fatty acid metabolism
acyl-CoA synthetase long-chain family member 1 NM_001995 1.84 3.49 1.90 0.82 1.72 2.09 0.88 2.30 2.60 0.82 1.00 1.23
carnitine palmitoyltransferase 1A (liver) NM_001876 1.48 2.86 1.93 0.37 2.05 5.60 0.74 1.35 1.83 1.12 1.24 1.10
solute carrier family 25 (carnitine/acylcarnitine 
translocase), member 20
NM_000387 1.20 2.23 1.85 0.91 1.36 1.50 0.83 0.93 1.12 1.04 1.27 1.22
acyl-Coenzyme A dehydrogenase, very long 
chain
NM_000018 2.16 3.46 1.60 0.92 2.69 2.93 1.36 1.97 1.45 1.55 2.33 1.50
acyl-Coenzyme A dehydrogenase, C-4 to C-12 
straight chain
NM_000016 1.62 2.52 1.56 0.64 2.03 3.16 1.24 1.48 1.20 1.40 1.80 1.29
hydroxyacyl-Coenzyme A dehydrogenase/3-
ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme 
A hydratase (trifunctional protein), alpha subunit
NM_000182 1.48 2.43 1.65 0.89 1.49 1.66 1.34 1.62 1.21 1.41 2.29 1.62
hydroxyacyl-Coenzyme A dehydrogenase/3-
ketoacyl-Coenzyme A thiolase/enoyl-Coenzyme 
A hydratase (trifunctional protein), beta subunit
NM_000183 1.74 2.66 1.53 0.95 1.30 1.36 1.17 1.49 1.27 1.14 1.62 1.42
acetyl-Coenzyme A acyltransferase 2 
(mitochondrial 3-oxoacyl-Coenzyme A thiolase)
NM_006111 1.58 1.92 1.21 1.06 1.63 1.53 0.89 1.31 1.47 1.18 2.44 2.06
acetyl-Coenzyme A acyltransferase 1 
(peroxisomal 3-oxoacyl-Coenzyme A thiolase)
NM_001607 1.42 1.62 1.14 0.68 1.47 2.15 1.22 2.07 1.70 1.42 2.01 1.41
enoyl Coenzyme A hydratase 1, peroxisomal NM_001398 2.28 2.61 1.15 0.99 2.05 2.07 1.16 1.46 1.26 1.44 1.98 1.38
Antioxidant
catalase NM_001752 1.51 2.36 1.56 0.68 1.45 2.13 1.06 1.54 1.45 1.69 2.59 1.53
vanin 1 NM_004666 5.07 12.92 2.55 0.68 1.91 2.80 2.42 6.02 2.49 1.77 5.70 3.23
Ketogenesis
3-hydroxy-3-methylglutaryl-Coenzyme A 
synthase 2 (mitochondrial)
NM_005518 32.40 156.62 4.83 1.13 2.51 2.22 2.14 6.57 3.07 2.20 6.53 2.96
Transport/strage
fatty acid binding protein 1, liver NM_001443 1.39 2.08 1.50 0.18 1.33 7.57 2.73 6.52 2.39 3.52 10.44 2.96
adipose differentiation-related protein NM_001122 1.96 3.44 1.75 0.22 2.90 13.02 3.33 6.06 1.82 3.40 5.73 1.68
C-terminal linking and modulating protein/PDZ 
domain containing 1
NM_002614 2.16 3.02 1.40 0.52 2.85 5.45 1.03 2.42 2.34 1.98 3.21 1.62
lipase, hepatic NM_000236 8.34 10.39 1.25 0.72 2.89 4.00 1.08 2.47 2.28 1.64 3.99 2.44
GluconeogenesisN
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aquaporin 3 NM_004925 3.00 5.86 1.95 0.26 1.91 7.38 1.58 3.41 2.16 1.38 3.09 2.24
glycerol kinase NM_000167 0.87 1.57 1.79 0.73 0.79 1.08 1.00 1.21 1.21 1.84 3.17 1.73
phosphoenolpyruvate carboxykinase 1 (soluble) NM_002591 6.39 17.90 2.80 0.83 4.64 5.56 6.94 29.19 4.20 34.46 110.78 3.21
Metabolism
angiopoietin-like protein 4 NM_016109 1.71 17.97 10.54 3.00 25.67 8.56 1.24 7.27 5.84 3.88 33.56 8.66
heme oxygenase (decycling) 1 NM_002133 1.25 2.21 1.77 0.66 1.25 1.90 1.31 2.20 1.68 2.18 4.20 1.93
biliverdin reductase B (flavin reductase 
(NADPH))
NM_000713 1.07 1.65 1.55 0.84 0.86 1.03 0.87 1.58 1.81 1.36 4.03 2.97
sulfotransferase family, cytosolic, 2A, 
dehydroepiandrosterone (DHEA) -preferring, 
member 1
NM_003167 2.61 2.86 1.10 0.70 2.08 2.98 0.95 1.76 1.85 1.71 1.68 0.98
abhydrolase domain containing 3 NM_138340 1.68 3.51 2.08 0.54 2.16 3.96 1.76 3.30 1.88 2.01 3.99 1.99
Table 1: Changes in mRNA expression levels of metabolism-related genes in HepG2-tet-off-hPPAR cells by ligands. Microarray analyses were performed on HepG2-tet-off-
hPPAR cells; the cells were cultured in the presence (Dox) or absence of Dox for 5 days. In the absence of Dox, the cells were treated with PPAR ligands (100 µM fenofibric acid 
for PPARα (Feno), 100 nM GW501516 for PPARδ (GW) or 10 µM ciglitizone for PPARγ (Cig)) or vehicle (DMSO) for 24 h. Gene expression profiles were compared between 
DMSO and Dox (DMSO versus Dox), ligands and Dox (Feno versus Dox, GW versus Dox, and Cig versus Dox were indicated in the case of PPARα, PPARδ and PPARγ, 
respectively) or ligands and DMSO (Feno versus DMSO, GW versus DMSO, and Cig versus DMSO were indicated in the case of PPARα, PPARδ and PPARγ, respectively). Samples 
were analysed using GeneChip® software Microarray Suite (MAS) Ver.5.0 (Affymetrix). (Continued)Nuclear Receptor 2005, 3:3 http://www.nuclear-receptor.com/content/3/1/3
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proliferation in these cell lines was not affected until 7
days after the removal of Dox. Based on these results, we
decided that the expression of each PPAR on the 5th day
was suitable for further analyses, such as the determina-
tion of the target genes of each PPAR subtype.
Changes in mRNA expression profiles by the induction of 
each PPAR subtype with the PPAR ligands
To characterize the regulation of gene expression by each
PPAR subtype, we performed oligonucleotide microarray
analyses. HepG2-tet-off-hPPAR cells were cultured in the
presence or absence of Dox for 5 days, then treated with
the PPAR ligands (100 µM fenofibric acid for PPARα, 100
nM GW501516 for PPARδ or 10 µM ciglitizone for
PPARγ) or vehicle for 24 h. Total RNA samples were pre-
pared from these cells, and oligonucleotide microarray
analyses were performed using the Affymetrix HG-U133A
arrays that contain >22,000 probe sets.
To identify human PPARs-responsive genes, we analysed
the genes induced by ligand-activated PPARs. The criteria
for selecting genes are described in the Methods section.
Based on these criteria, 29, 21, 60 and 107 genes were up-
regulated by ligand-activated PPARα, PPARδ, PPARγ1 and
PPARγ2, respectively. As shown in Table 1 and the addi-
tional file 1, each PPAR affects the expression levels of sev-
eral genes involved in lipid metabolism, glucose
homeostasis, etc. PPARα tends to induce the expression of
a number of genes involved in the β-oxidation of fatty
acids by mitochondria, peroxisomal fatty acid oxidation,
antioxidant and ketogenesis. Most of the genes that were
induced by PPARδ were similar to those exhibited by
PPARα. We observed that induced expression of PPARδ
increased the expression in the presence of the ligand,
while unliganded PPARδ repressed the expression of its
target genes instead. On the other hand, PPARγ tends to
induce the expression of several genes involved in gluco-
neogenesis, lipid storage, transport and metabolism.
Moreover, PPARγ is likely to induce several genes involved
in angiogenesis, cytoskeleton organization, protein mod-
ification, regulation of transcription, signal transduction,
etc.
Verification of gene expression profiles with quantitative 
PCR analyses
The expression of a subset of genes in response to treat-
ment with PPAR ligands was further characterized using
real-time quantitative PCR analyses. Total RNA samples
were prepared from HepG2-tet-off-hPPAR cells, which
were cultured in the presence or absence of Dox for 5 days,
and subsequently treated with the PPAR ligands (100 µM
fenofibric acid, 100 nM GW501516 or 10 µM ciglitizone
for PPARα, PPARδ and PPARγ, respectively) or vehicle for
0, 8, 24, 48 or 72 h. Several PPAR-responsive genes
(ADRP, 3-hydroxy-3-methylglutaryl-Coenzyme A
synthase 2 (mitochondrial) (HMGCS2), hydroxyacyl-
Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thi-
olase/enoyl-Coenzyme A hydratase (trifunctional pro-
tein),  α subunit (HADHA), phosphoenolpyruvate
carboxykinase 1 (PEPCK), acyl-Coenzyme A dehydroge-
nase, C-4 to C-12 straight chain (MCAD), angiopoietin-
like protein 4 (ANGPTL4), fatty acid binding protein 1,
liver (L-FABP)) were up-regulated by the expression of
PPARα and PPARγ (Figure 3). On the other hand, only lig-
and-activated PPARδ induced the expression of these
genes, but unliganded PPARδ repressed them, in agree-
ment with microarray analyses (Figure 3B and Table 1).
Although until now C-terminal linking and modulating
protein/PDZ domain containing 1 (CLAMP/PDZK1)
mRNA has not been reported as a target for PPARs, we
observed that PPARs induced CLAMP/PDZK1 mRNA by
microarray analyses (Table 1). We, therefore, verified the
expression of CLAMP/PDZK1 mRNA using real-time
quantitative PCR analysis. A similar result was observed
on the expression pattern of CLAMP/PDZK1 mRNA (Fig-
ure 3).
Although all subtypes of PPARs could induce the expres-
sion of these genes, PPARα was more effective than other
subtypes in the real-time PCR analyses (Figure 3).
PPARs modulate human ADRP promoter activity via a 
PPRE
To determine whether one of these genes was regulated by
PPARs directly, we performed transient transfection exper-
iments with the human ADRP promoter. It has been
reported that the mouse ADRP promoter contains a func-
tional PPRE [11]. Examination of the corresponding
region of the human adrp gene indicated that the essential
features of this element are likely to be conserved, and we
found that the human ADRP promoter contained a poten-
tial PPRE at positions -2361 to -2345 (Figure 4A).
To analyse whether this site can be regulated by PPARs,
either the wild type 4-kb fragment of the human ADRP
promoter (hADRP-4K), deletion promoter (hADRP-d1)
whose potential PPRE is deleted or mutation promoter
(hADRP-mut) whose potential PPRE is mutated, was
cloned in front of the pGL3-luciferase reporter gene to
construct reporter plasmids (Figure 4B). We co-transfected
either the PPAR expression plasmid (pcDNA3-hPPARα,
pcDNA3-hPPARδ, pcDNA3-hPPARγ1 or pcDNA3-
hPPARγ2) or the vector plasmid (pcDNA3) as a control
together with each reporter plasmid into HepG2 cells, and
subsequently incubated these cells with or without lig-
ands (100 µM fenofibric acid, 100 nM GW501516 or 10
µM ciglitizone for PPARα, PPARδ and PPARγ, respec-
tively) for 24 h. Ligand-activated PPARs induced the pro-
moter activity of the wild type 2 to 5-fold higher than theNuclear Receptor 2005, 3:3 http://www.nuclear-receptor.com/content/3/1/3
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Eight gene expressions were modulated by PPARs in tet-regulated HepG2 cells Figure 3
Eight gene expressions were modulated by PPARs in tet-regulated HepG2 cells. A, B, C and D, HepG2-tet-off-
hPPAR cells were treated with DMSO (vehicle) or PPAR ligands (100 µM fenofibric acid for PPARα (A), 100 nM GW501516 
for PPARδ (B), 10 µM ciglitizone for PPARγ1 (C) or PPARγ2 (D)) for 0, 8, 24, 48 or 72 h in the absence of Dox. Messenger 
RNA levels of human ADRP, HMGCS2, HADHA, PEPCK, MCAD, ANGPTL4, L-FABP and CLAMP/PDZK1 were measured by 
real time RT-PCR. Values are expressed as mean ± S.E.M. (n = 3) target mRNA levels normalized to GAPDH mRNA.Nuclear Receptor 2005, 3:3 http://www.nuclear-receptor.com/content/3/1/3
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PPARs modulate human ADRP promoter activity via a PPRE located between -2361 and -2345 bp Figure 4
PPARs modulate human ADRP promoter activity via a PPRE located between -2361 and -2345 bp. A, A 
sequence corresponding to the -2366/-2339 region of the human adrp gene, was compared with a consensus PPRE and the 
analogous regions in the mouse adrp gene promoter (-2013/-1986). A human ADRPmut indicates a human ADRP promoter 
whose potential PPRE was mutated. Asterisks denote conserved bases and arrows represent response element half-sites. B, 
Schematic representation of the chimeric genes containing the human ADRP promoters; each wild type (hADRP-4K), point 
mutation (hADRP-mut), and deletion (hADRP-d1) of the ADRP promoter was cloned in front of the firefly luciferase reporter 
gene. Lowercase letters indicate mutations introduced in the human ADRP PPRE. C, D, E and F, HepG2 cells were co-transfected 
with a human ADRP reporter plasmid (50 ng), phRL-TK (50 ng) and either pcDNA3-hPPARα (5 ng) (C), pcDNA3-hPPARδ (5 
ng) (D), pcDNA3-hPPARγ1 (5 ng) (E) or pcDNA3-hPPARγ2 (5 ng) (F). Transfected cells were treated with ligands (100 µM 
fenofibric acid (C), 100 nM GW501516 (D) or 10 µM ciglitizone (E and F)) for 24 h and the cells were used for reporter gene 
assays. Luciferase activities from reporter plasmids were normalized by internal Renilla luciferase activity. Values are expressed 
as fold induction of the control (the value when only reporter plasmid (ADRP-4K) was transfected) set at 1. Values represent 
the mean ± S.E.M. (n = 3).


Luc PPRE
-2981 +1066
-2361 -2345
hADRP-4K
Luc
-2345
hADRP-d1
hADRP-mut
B
0
1
2
3
4
R
e
l
a
t
i
v
e
 
L
u
c
i
f
e
r
a
s
e
A
c
t
i
v
i
t
y
PPARa1
Ciglitizone
hADRP-4K + ++ +- - - -- - - -
hADRP-d1 + + + + -- - -- - - -
+ + + + -- - -+ + --
++ ++ - -- - + + --
hADRP-mut - - - -- - - -+ + + +
PPARa1
0
1
2
3
4
R
e
l
a
t
i
v
e
 
L
u
c
i
f
e
r
a
s
e
A
c
t
i
v
i
t
y
PPARa2
Ciglitizone
hADRP-4K + ++ +- - - -- - - -
hADRP-d1 + + + + -- - -- - - -
+ + + + -- - -+ + --
++ ++ - -- - + + --
hADRP-mut - - - -- - - -+ + + +
PPARa2 EF
0
0.5
1.0
1.5
2.0
2.5
R
e
l
a
t
i
v
e
 
L
u
c
i
f
e
r
a
s
e
A
c
t
i
v
i
t
y
hADRP-4K + ++ +- - - -- - - -
hADRP-d1 + + + + -- - -- - - -
PPARb + + + + -- - -+ + --
GW501516 + + ++ - -- - + + --
hADRP-mut - - - -- - - -+ + + +
PPARb
0
2
4
6
8
R
e
l
a
t
i
v
e
 
L
u
c
i
f
e
r
a
s
e
A
c
t
i
v
i
t
y
hADRP-4K + ++ +- - - -- - - -
hADRP-d1 + + + + -- - -- - - -
PPAR_ + + + + -- - -+ + --
Fenofibric
Acid
++ ++ - -- - + + --
hADRP-mut - - - -- - - -+ + + +
PPAR_ CD
 mouse ADRP : -2013 -1986
DR1
			
 Consensus :
5'Flank
human ADRP : -2366 -2339 
human ADRPmut : 






















W = A or T,   R = A or G,   K = G or T,   M = A or C
PPRE ANuclear Receptor 2005, 3:3 http://www.nuclear-receptor.com/content/3/1/3
Page 10 of 17
(page number not for citation purposes)
control (no PPAR expression without ligand) (Figure 4C–
F). Interestingly, the expression of PPARδ without ligand
diminished the wild type ADRP reporter gene expression
to about 60% of the control in HepG2 cells (Figure 4D).
We did not detect this observation when either deleted or
mutated PPRE reporter plasmid was used. These data indi-
cate that this PPRE in the ADRP promoter is a cis-acting
element by which PPARs modulate human ADRP pro-
moter activity.
To determine whether human PPARs/RXRα heterodimers
bind this PPRE in the ADRP promoter, EMSAs were per-
formed using this response element as a radiolabelled
probe (Figure 5A–D). EMSAs revealed that all PPAR sub-
types could bind the PPRE of the ADRP promoter in the
presence of RXRα (closed arrowhead on lanes 2 to 4). Fur-
thermore, these complexes were supershifted by anti-
PPAR antibodies (open arrowhead on lane 5). This com-
plex formation was competed by increasing amounts (10-
and 100-fold excess) of unlabeled self-competitor (ADRP)
and rat acyl CoA oxidase (ACO) PPRE fragments, but not
by the mutated PPRE (ADRPmut) probes (lanes 6 to 11).
Furthermore, no protein-DNA complex was observed
when using the mutated PPRE (ADRPmut) probe (lane
12). Taken together, these data demonstrate that all
PPARs bind to the same PPRE site at the position -2361 to
-2345, and modulate human ADRP promoter activity.
To confirm that the PPARs/RXRα heterodimers bind to
the PPRE in the ADRP promoter in vivo, we performed
chromatin immunoprecipitation (ChIP) assays using an
anti-PPARα, anti-PPARδ, anti-PPARγ, or anti-RXRα anti-
body. HepG2-tet-off-hPPAR cells were cultured in the
absence of Dox for 5 days, and were subsequently treated
with the PPAR ligands (100 µM fenofibric acid, 100 nM
GW501516 or 10 µM troglitazone for PPARα, PPARδ and
PPARγ, respectively) for 8 h and subsequently used for
ChIP assays. PPARs/RXRα heterodimers bound to the
PPRE in the ADRP promoter in vivo (Figure 6).
Discussion
In the present study, in order to identify human PPARs-
responsive genes in the liver, we have established tightly
tet-regulatable human hepatoblastoma cell lines that can
be induced to express each human PPAR (HepG2-tet-off-
hPPAR cells). DNA microarray and real-time RT-PCR
analyses using these stable cell lines indicate that PPARs
activate gene expression involved in lipid metabolism,
glucose homeostasis, and other activities (Table 1 and Fig-
ure 3). Cell proliferation of these cell lines was not
affected until 7 days after removal of Dox. However, fur-
ther investigation is required to define the influence of the
expression of PPARs on the proliferation of these cell
lines.
We identified a series of genes that are critical for many
aspects of carbohydrate and lipid metabolism, including
intracellular fatty acid transport, mitochondrial fatty acid
β-oxidation, and ketogenesis by PPARα (Table 1). Indeed,
PPARα regulates the expression of genes that encode for
enzymes involved in peroxisomal proliferation and fatty
acid oxidation in peroxisomes and mitochondria [2]. In
addition, PPREs are present in the promoter region or the
intronic sequence of these target genes [4]. However, our
results show that PPARα and other PPAR subtypes induce
expression of these genes. In fact, liver PPARγ regulated
the expression levels of genes involved in lipogenesis,
fatty acid transport, storage, and oxidation using both
wild type mice and adipose-deficient mice [23]. Other
reports also showed that PPARδ induced fatty acid oxida-
tion by regulating genes involved in fatty acid transport, β-
oxidation, and mitochondrial respiration in various tis-
sues [7-9]. These reports support our results whereby each
PPAR subtype induces fatty acid oxidation in the
hepatoblastoma cell lines. In the real-time PCR analyses
PPARα was more effective than other subtypes in the
hepatoblastoma cell lines, although all subtypes could
induce the expression of these genes (Figure 3). Thus, we
assume that PPARα plays a major role in the liver, how-
ever, the mechanism of this effect remains uncertain.
Mammalian cells use glucose as a major energy source,
and the origin of hepatic glucose production shifts from
mainly glycogenolysis to gluconeogenesis as fasting pro-
longs to maintain blood glucose levels. The main precur-
sors for hepatic gluconeogenesis are lactate, pyruvate,
glycerol and alanine, which are converted into glucose via
a series of reactions in the cytosol and mitochondria.
PPARα plays a pivotal role in the management of energy
stores during fasting [2]. Indeed, PPARα-null mice, fasted
for 24 h, exhibit severe hypoglycaemia [24,25]. Recently,
Patsouris et al. demonstrated that PPARα stimulates the
expression of a set of genes involved in hepatic gluconeo-
genesis from glycerol [26]. In the present study, glycerol
kinase and glycerol transporter aquaporin 3 were up-reg-
ulated by the liganded PPARs. Surprisingly, an unexpected
finding was that the PEPCK was up-regulated by PPARs in
these cell lines. PEPCK catalyses the rate-limiting step in
liver gluconeogenesis. Way et al. showed that when Zucker
diabetic fatty rats were treated with PPARγ agonists,
PEPCK expression was decreased in the liver, and sug-
gested that PPARγ agonists decrease gluconeogenesis [27].
Although we cannot fully explain this inconsistency, there
are several reports, which support our results. An in vivo
study showed that PEPCK mRNA levels are elevated in the
livers of dexamethasone (DEX)-treated PPARα+/+ mice,
and not DEX-treated PPARα-/- mice, and that PEPCK is
increased when hepatic PPARα expression is reconstituted
in DEX-treated PPARα-/-LDLR-/- mice. Furthermore, the
combination of DEX and the potent PPARα ligandNuclear Receptor 2005, 3:3 http://www.nuclear-receptor.com/content/3/1/3
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PPARs bind to the PPRE in the -2366/-2339 region of the human adrp gene Figure 5
PPARs bind to the PPRE in the -2366/-2339 region of the human adrp gene. A, B, C and D, EMSAs were performed 
with 32P-labelled either ADRP or mutated ADRP (ADRPmut) oligonucleotides in the presence of purified PPARα (A), purified 
PPARδ (B), in vitro transcribed/translated PPARγ1 (C), purified PPARγ2 (D) and/or purified RXRα proteins. Supershift experi-
ments were carried out using anti-PPARα (A), anti-PPARδ (B) or anti-PPARγ (C and D) antibodies. Unlabelled oligonucleotides 
(ADRP, ADRPmut or ACO) were used at 10- or 100-fold molar excess to the labelled probe to perform competition assays. 
Closed and open arrowheads indicate the specific bands and the supershift bands, respectively.Nuclear Receptor 2005, 3:3 http://www.nuclear-receptor.com/content/3/1/3
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Wy14,643 increased the expression of PEPCK in human
hepatocytes [28]. However, the reason for this differential
induction remains unknown.
CLAMP, a four-PDZ-domain-containing protein also
called PDZK1 [29], was identified as the scavenger recep-
tor class B type I (SR-BI)-associated protein from rat liver
membrane extracts [30]. CLAMP/PDZK1 regulates the sta-
ble SR-BI protein expression by a post-transcriptional
mechanism [31]. The hepatic expression of SR-BI plays a
critical role in lipoprotein metabolism, mainly due to its
ability to mediate selective high density lipoproteins
(HDL) cholesterol uptake [32,33]. HDL removes
cholesterol from peripheral tissues and then transfers it to
the liver. CLAMP/PDZK1 may modulate the intracellular
transport and metabolism of cholesteryl esters taken up
from HDL. Although until now, clamp/pdzk1 has not been
reported as a direct PPAR target gene, we observed that
CLAMP/PDZK1 mRNA was induced by PPARs in the
established cell lines (Table 1 and Figure 3). These data
suggest that CLAMP/PDZK1 is a target gene of PPARs. In
the case of humans, PPRE exists in the CLAMP/PDZK1
promoter and PPARs can directly bind to this region
(unpublished data). Therefore, PPAR activators may play
a role in the regulation of HDL metabolism. However, fur-
ther investigations are required to define the molecular
mechanisms underlying the PPAR-mediated HDL
metabolism.
Our microarray analyses indicated that there are many
genes which are induced by all PPAR subtypes (Table 1,
additional file 1). However, PPARα and PPARδ tend to
induce the expression of a number of genes involved in
the β-oxidation of fatty acids by mitochondria and perox-
isomal fatty acid oxidation, and PPARγ tends to induce
the expression of several genes involved in gluconeogene-
sis, lipid storage, transport and metabolism. Interestingly,
we also observed that the genes involved in angiogenesis,
cytoskeleton organization, signal transduction, protein
modification and regulation of transcription were up-reg-
ulated in our HepG2-tet-off-hPPARγ cell lines. Indeed,
there are several reports that PPARγ ligands modulate ang-
iogenesis [34]. Further investigation is necessary to certify
the subtype specific function of PPARs.
In the present study, we also observed that ligand-acti-
vated PPARδ induced target gene expression, however,
unliganded PPARδ repressed these genes in the estab-
lished cell lines (Table 1, Figures 3, 4). It has been
reported that unliganded PPARδ binds to PPRE and
recruits corepressors, such as a silencing mediator for
retinoid and thyroid hormone receptor (SMRT), nuclear
receptor corepressor (NCoR) etc. On the other hand, lig-
anded PPARδ is thought to release the corepressor and
form a complex with coactivators [35,36]. From this view-
point, these established cell lines have a potential applica-
tion to provide a high-throughput screening to detect the
PPARδ ligands (see below).
To further investigate the regulation of target gene expres-
sion by PPARs, we analysed the human ADRP promoter in
detail. ADRP, expressed ubiquitously, is a protein cover-
ing lipid droplets [37]. The mouse adrp gene exhibits a
PPRE between -2004 and -1992 bp that binds PPARs/RXR
heterodimers [11]. The sequence of the corresponding
response element in the human gene between -2361 and
-2345 bp is very similar to the mouse PPRE (Figure 4A).
We performed EMSAs with this element and all PPAR sub-
types bound to the same PPRE site of the ADRP promoter
(Figure 5). Moreover, this human PPRE site confers trans-
activation by PPARs to a luciferase reporter gene, and
mutations that disrupt the binding sequence of PPARs/
Chromatin immunoprecipitation assays of the ADRP  promoter Figure 6
Chromatin immunoprecipitation assays of the ADRP 
promoter. HepG2-tet-off-hPPAR cells were treated with 
PPAR ligands (100 µM fenofibric acid for PPARα, 100 nM 
GW501516 for PPARδ, or 10 µM troglitazone for PPARγ) 
for 8 h in the absence of Dox and processed for the ChIP 
assays. Soluble chromatin was immunoprecipitated with pre-
immune rabbit IgG (lanes 2 and 6), anti-PPAR antibodies 
(lanes 3 and 7), or anti-RXRα antibody (lanes 4 and 8). 
Immunoprecipitates were subjected to PCR with a primer-
pair specific to the ADRP promoter. As a negative control, a 
second set of primers were used to amplify another genomic 
region that was not expected to interact with the PPARs. 
PCR was performed with total chromatin input (lanes 1 and 
5).Nuclear Receptor 2005, 3:3 http://www.nuclear-receptor.com/content/3/1/3
Page 13 of 17
(page number not for citation purposes)
RXR on this PPRE abolish transactivation (Figure 4). Dur-
ing the preparation of this manuscript, it was reported
that the ADRP PPRE was the functional PPAR binding site
and could be activated by human PPARα and δ [38]. In
the present study, we showed the same result and that
PPARγ1 and γ2 can also bind to PPRE and regulate the
expression of the human adrp gene. Moreover, we were
the first to confirm that PPARs/RXRα heterodimers bind
to the PPRE in the ADRP promoter in vivo using ChIP
assays (Figure 6).
PPARs are linked to metabolic disorders and, therefore,
are interesting pharmaceutical targets. Among the syn-
thetic ligands that activate these receptors, the fibrates are
hypolipidemic compounds that activate PPARα. The thia-
zolidinediones, which selectively activate PPARγ, are
hypoglycaemic molecules that are used to treat type II dia-
betes. Recently, we and other groups reported that PPARδ
agonists might form effective drugs for obesity, diabetes,
and cardiovascular disease [7-9,39,40]. From this
viewpoint, these established cell lines have a potential
application in various high-throughput assays. For
instance, the reporter gene assay using the reporter plas-
mid containing the ADRP promoter would provide a use-
ful detection system of PPARδ ligands as potential drug
candidates in the HepG2-tet-off-hPPARδ cell line [41].
Conclusion
In conclusion, we established tightly tet-regulatable
human hepatoblastoma cell lines that can be induced to
express each human PPAR. These cell lines provided evi-
dence that human PPARs are important regulators of lipid
and glycerol homeostasis and new insights about the can-
didate target genes of PPARs. Therefore, these cell lines are
powerful tools for analysing the function of human
PPARs.
Methods
Materials
Fenofibric acid and GW501516 were synthesized as
described previously [7]. Ciglitizone was purchased from
Sigma. Troglitazone was purchased from Cayman
Chemical.
Plasmid Constructs
Construction of pcDNA3-hPPARα, pcDNA3-hPPARδ,
pcDNA3-hPPARγ1 and pcDNA3-hPPARγ2 expression
plasmids were described previously [42]. Human PPARs
fragments were excised from pcDNA3-hPPAR vectors.
pBI-EGFP (Clontech) was digested with PvuII, and ligated
with the PPAR fragment (termed pBI-EGFP-hPPAR).
To generate human ADRP promoter-reporter plasmids,
human ADRP promoter containing -2981 to +1066 bp
(hADRP-4K) and the deletion promoter containing -2345
to +1066 bp (hADRP-d1) were obtained by means of PCR
with the bacterial artificial chromosome (BAC) clone
plasmid (BACPAC resource center at Children's Hospital
Oakland Research Institute) using a forward primer 5'-
GGTACCTATCCCTGGTGCCAAAAAGGTTGGGGA-3'
(including a KpnI site, underlined) for hADRP-4K or a for-
ward primer 5'-GGTACCGAGAGTCTTCTGATGCAAAG-
TAAGAGG-3' (including a KpnI site, underlined) for
hADRP-d1 and a reverse primer 5'-AGATCTTTTTCTTCCT-
GGAGAAAGAAATCTGCAGAAAAGAG-3' (including a
BglII site, underlined). Each promoter was cloned into the
KpnI-BglII sites of a pGL3-Basic vector (Promega). A point
mutation was introduced into the ADRP promoter by PCR
methodology. To generate a point-mutation construct
(pGL3-hADRP-mut), a 101 bp mutant fragment was gen-
erated from forward primer (5'-GCAAAAAGAAGCTTGCT-
CAG-3') and reverse primer (5'-
GACTCTCGCCCTTaagCtTgCggAATG-3') (Mutated bases
are shown as lowercase letters). Then using this 101 bp
mutant fragment for a forward primer, we amplified a
1273 bp mutant fragment using a reverse primer (5'-
GTGCAGGGTTATGCATTGTT-3'). The 1273 bp mutant
fragment was digested with Bpu1102I and EcoT22I, and
then the fragment was inserted into the Bpu1102I/
EcoT22I-digested pGL3-hADRP-4K vector.
Nucleotide sequences of these plasmids were confirmed
by ABI PRISM®  310 Genetic Analyzer (Applied
Biosystems).
Cell culture
HepG2 cells were cultured in DMEM (Nacalai tesque)
containing 10% heat-inactivated charcoal/dextran treated
foetal bovine serum (FBS) (HyClone), 100 IU/ml
penicillin and 100 µg/ml streptomycin. The tightly tet-reg-
ulatable HepG2 cell clone (HY-Toff) which was trans-
fected with the pTet-off vector, was isolated as previously
described [22]. HY-Toff cells were co-transfected with pBI-
EGFP-hPPAR and pBabepuro using TransIT®-LT1 Transfec-
tion Reagents (Mirus). The cells were cultured in a
medium containing 600 µg/ml G418 (Nacalai tesque), 1
µg/ml puromycin (Sigma) and 1 µg/ml Dox (Clontech).
G418- and puromycin-resistant clones were isolated.
These clones were further screened for well-inducible
clones by checking the expression of EGFP using fluores-
cence microscopy and the expression of PPAR proteins
using immunoblot analysis in the absence of Dox.
Quantitative Real-Time PCR
Total RNA was isolated using an RNA preparation kit (Iso-
gen; Nippon Gene Corp.). First strand cDNA was synthe-
sized from 5 µg of total RNA of each cell sample using the
SuperScript™ First-Strand Synthesis System for RT-PCR
(Invitrogen) with oligo(dT)12–18 primer. The cDNAs were
then used as templates for individual PCR reactions usingNuclear Receptor 2005, 3:3 http://www.nuclear-receptor.com/content/3/1/3
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specific primer sets (Table 2), which were designed by the
Primer3 program written by the Whitehead Institute [43].
PCR reactions were carried out using QuantiTect™ SYBR®
Green PCR Kit (Qiagen). The quantitative PCR analysis
was performed using the DNA Engine Opticon™ System
(Bio-Rad Laboratories). Amplification specificity was ver-
ified by visualizing PCR products on an ethidium bro-
mide-stained 3% agarose gel. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used for
normalizing each expression data.
Immunoblot Analysis
Nuclear extracts were obtained as previously described
[44]. Each nuclear extract (50 µg) was resolved by 10%
SDS-PAGE, and electroblotted to nitrocellulose mem-
branes. Western blot analyses were carried out using anti-
human PPARα [H0723], PPARδ [K7701] (Perseus Pro-
teomics Inc.) or PPARγ [E-8] antibodies (Santa Cruz). The
signals were visualized with the ECL detection system
(Amersham Biosciences).
Affymetrix Oligonucleotide Microarray Analysis
HepG2-tet-off-hPPAR cells were cultured in the presence
(Dox) or absence of Dox for 5 days. In the case of the
absence of Dox, the cells were treated with PPAR ligands
(100  µM fenofibric acid for PPARα (Feno), 100 nM
GW501516 for PPARδ ( G W )  o r  1 0  µM ciglitizone for
PPARγ (Cig)) or vehicle (DMSO) for 24 h. Total RNA sam-
ples were prepared from these cells using an RNA prepara-
tion kit (Isogen). Hybridization samples were prepared
according to the Affymetrix protocol as previously
described [7]. Briefly, 10 µg total RNA was used to
generate first-strand cDNA. After second-strand cRNA syn-
thesis, biotinylated and amplified RNAs were purified
using RNeasy (Qiagen) and quantitated by a spectropho-
tometer. Biotinylated cRNA samples were then hybridized
to Affymetrix Human Genome U133A arrays. These arrays
contain probe sets for >22,000 transcripts and EST clones.
After hybridization, microarrays were washed, scanned,
and analysed with the GeneChip® software Microarray
Suite (MAS) Ver.5.0 (Affymetrix). The criteria for selecting
genes that were induced by ligand-activated PPARs were
as follows: (1) in the presence of ligand, the average dif-
ference of gene was ≥ 100 and the gene represented as
"presence"; (2) the ratio of the expression level in the pres-
ence of ligand to the expression level in the presence of
Dox was greater than two; and (3) the ratio of the expres-
sion level in the presence of ligand to the expression level
Table 2: Primers used for Real-Time PCR Analysis. Sequences of forward (For.) and reverse (Rev.) primer for each target are shown. 
Sequences are 5' to 3'.
Gene Sequence Size (bp)
ADRP For. primer : TGAGATGGCAGAGAACGGTGTG 184
Rev. primer : GGCATTGGCAACAATCTGAGT
ANGPTL4 For. primer : GGGAGAGGCAGAGTGGACTATTT 96
Rev. primer : TTACTGTCCAGCCTCCATCTGA
CLAMP/PDZK1 For. primer : CTAAACTCTGCAGGCTGGCTAAA 101
Rev. primer : GCCCTTCTGTACCTCTTTGATGA
HADHA For. primer : CAAGGGCTTCCTAGGTCGTAAAT 155
Rev. primer : GGAACTGGATGTCTTCGTCTGAT
HMGCS2 For. primer : GGAACCCATATGGAGAATGTGT 168
Rev. primer : ATCGCTGCCAGCTTGCTT
GAPDH For. primer : TGGGTGTGAACCATGAGAAG 76
Rev. primer : GCTAAGCAGTTGGTGGTGC
L-FABP For. primer : TTGCCACCATGAGTTTCTCCG 82
Rev. primer : GGCAGACCGATTGCCTTCA
MCAD For. primer : TTCCAGAGAACTGTGGAGGTCTT 100
Rev. primer : TCAATAGCAGTCTGAACCCCTGT
PEPCK For. primer : TGCATGAAAGGTCGCACCA 192
Rev. primer : CACAGAATGGAGGCATTTGACA
PPARα For. primer : CTATCATTTGCTGTGGAGATCG 121
Rev. primer : AAGATATCGTCCGGGTGGTT
PPARδ For. primer : GTCACACAACGCTATCCGTTT 143
Rev. primer : AGGCATTGTAGATGTGCTTGG
PPARγ1 For. primer : CGTGGCCGCAGATTTGAA 166
Rev. primer : CTTCCATTACGGAGAGATCCAC
PPARγ2 For. primer : GGTGAAACTCTGGGAGATTCT 102
Rev. primer : CTCTGTGTCAACCATGGTCANuclear Receptor 2005, 3:3 http://www.nuclear-receptor.com/content/3/1/3
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in the absence of ligand was greater than 1.5. Raw data are
available at NCBI GEO, web page accession number
GSE2699.
Luciferase Assay
HepG2 cells were transfected using Lipofectamine™ 2000
(Invitrogen) according to the manufacturer's instructions.
HepG2 cells (3 × 104 cells/well) were seeded in 96-well
plates 14–18 h before transfection. The cells were trans-
fected with 50 ng of human ADRP reporter plasmid, 50 ng
of phRL-TK (Promega) and either 5 ng of pcDNA3,
pcDNA3-hPPARα, pcDNA3-hPPARδ, pcDNA3-hPPARγ1
or the pcDNA3-hPPARγ2 expression vector. Twenty-four
hours following transfection, the cells were incubated
with a medium containing dimethylsulfoxide (DMSO)
(vehicle), 100 µM fenofibric acid, 100 nM GW501516 or
10 µM ciglitizone. Following a period of 24 h, both firefly
and Renilla  luciferase activities were quantified using a
Dual-Luciferase®  Reporter Assay System (Promega)
according to manufacturer's instructions.
Electrophoretic Mobility Shift Assay (EMSA)
Human PPARα, human PPARδ, human PPARγ2 and
human RXRα proteins were prepared using the IMPACT™-
CN system (New England Biolabs). Human PPARγ1 pro-
tein was synthesized in vitro using the TNT® Quick Cou-
pled Transcription/Translation Systems (Promega).
Double-strand oligonucleotides were labelled with [α-
32P]dCTP and a Klenow fragment and were used as
probes. PPARα, PPARδ, PPARγ1, PPARγ2 and/or RXRα
proteins were incubated with 32P-labelled probe in a total
volume of 12.5 µl binding buffer (10 mM Tris-HCl (pH
7.5), 5% glycerol, 1 mM DTT, 1 mM EDTA, 1 µg poly (dI-
dC), 30 µg BSA) at room temperature for 30 min, fol-
lowed by an incubation at 4°C for 30 min. Supershift
assays were performed by adding antibodies 1 h before
incubation with an oligonucleotide probe at room tem-
perature. All monoclonal antibodies (PPARα [H0723],
PPARδ [K9418], PPARγ [A3408A]) were obtained from
Perseus Proteomics. In competition studies, the proteins
were pre-incubated with 10- or 100-fold molar excess of
unlabelled wild-type or mutant oligonucleotides. Protein-
DNA complexes were resolved on a 5% nondenaturing
polyacrylamide gel in 1 × TAE buffer. The loaded gel was
fixed with 10% methanol and 10% acetic acid, and then
the gel was dried and autoradiographed. Double-stranded
oligonucleotides composed of the following sequences
were used for the binding and competition assays: human
ADRP PPRE wild type, 5'-GCATTTTGTAGGTGAAAG-
GGCGAGAGTC-3'; ADRP PPRE mutant, 5'-GCATTccG-
cAaGcttAAGGGCGAGAGTC-3', and rat acyl-CoA oxidase
(ACO) PPRE wild type, 5'-GCGGACCAGGACAAAGGT-
CACGTTC-3' (Mutated bases are shown as lowercase
letters).
Chromatin Immunoprecipitation (ChIP) Assay
HepG2-tet-off-hPPAR cells were cultured in the absence of
Dox for 5 days. The cells were treated with PPAR ligands
(100 µM fenofibric acid for PPARα, 100 nM GW501516
for PPARδ, or 10 µM troglitazone for PPARγ) for 8 h. Cells
were fixed in vivo at room temperature for 10 min by the
addition of formaldehyde at a final concentration of 1%
directly onto the cell culture media. Fixation was com-
pleted following the addition of glycine with a 0.125 M
final concentration and the incubation was continued for
a further 5 min. The cells were washed twice using ice-cold
phosphate-buffered saline and collected. The cell pellets
were washed with cell lysis buffer (10 mM Tris-HCl (pH
7.5), 10 mM NaCl, 3 mM MgCl2, 0.5% NP-40, and a
protease inhibitor cocktail (Sigma)) three times, and dis-
solved in SDS lysis buffer (10 mM Tris-HCl (pH 7.5), 270
mM NaCl, 3 mM MgCl2, 1 mM CaCl2, 4% NP-40, 1.3%
SDS, and a protease inhibitor cocktail) and remained on
ice for 10 min. The cell lysates were sonicated to shear
chromosomal DNA with an average length of 1000 bp.
After centrifugation to remove insoluble materials, the
chromatin solution was diluted 10-fold in an IP dilution
buffer (20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM
EDTA, 1% Triton X-100, 0.01% SDS, and a protease inhib-
itor cocktail), and the diluted solution was pre-cleared
with protein G Sepharose beads on a rotating wheel at
4°C for 1 h. Beads were removed by centrifugation and
the supernatants were incubated with 2 µg of antibodies
to PPARα (H-98, Santa Cruz), PPARδ (H-74, Santa Cruz),
PPARγ (H-100, Santa Cruz), or RXRα (D-20, Santa Cruz)
at 4°C overnight. For a negative control, pre-immune rab-
bit IgG (Santa Cruz) was incubated with the supernatant.
The complexes were immunoprecipitated with protein G
Sepharose beads. The beads were washed once with IP
dilution buffer, twice with wash buffer 1 (20 mM Tris-HCl
(pH 8.0), 150 mM NaCl, 2 mM EDTA, 1% Triton X-100,
0.1% SDS, and a protease inhibitor cocktail), once with
wash buffer 2 (20 mM Tris-HCl (pH 8.0), 500 mM NaCl,
2 mM EDTA, 1% Triton X-100, 0.1% SDS, and a protease
inhibitor cocktail), once with wash buffer 3 (10 mM Tris-
HCl (pH 8.0), 1 mM EDTA, 0.25 M LiCl, 1% NP-40, 1%
deoxycholate), and twice with TE buffer. Immune com-
plexes were eluted from the beads in the elution buffer
(25 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.5% SDS, 10
mM DTT) for 15 min. The proteins were removed from
DNA by digesting with 1.5 mg/ml pronase at 42°C for 2
h. The crosslink was reversed by adding 5 M NaCl to a
final concentration of 200 mM followed by incubation at
65°C for 6 h. The sample DNAs were then extracted with
phenol-chloroform-isoamyl alcohol (25:24:1), precipi-
tated with ethanol in the presence of glycogen, and resus-
pended in TE buffer. Similarly purified DNA fragments
from the chromatin extracts (input) were used as a control
for PCR reactions. Precipitated DNAs were analysed by
PCR of 32 cycles using primers 5'-GCAAAAAGAAGCTT-Nuclear Receptor 2005, 3:3 http://www.nuclear-receptor.com/content/3/1/3
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GCTCAG-3' and 5'-TGTTGCCATCTTCAGTGTTT-3' that
flanked the PPRE of the ADRP promoter or primers 5'-
ATGGTTGCCACTGGGGATCT-3' and 5'-
TGCCAAAGCCTAGGGGAAGA-3' that are located about
6-kb upstream of the GAPDH promoter (negative con-
trol). PCR products were separated on a 2% agarose gel
and stained with ethidium bromide.
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